Abeona Therapeutics (NASDAQ:ABEO) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note published on Friday, Benzinga reports. The brokerage currently has a $15.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on ABEO. Stifel Nicolaus assumed coverage on shares of Abeona Therapeutics in a research note on Thursday, May 30th. They set a buy rating and a $21.00 target price for the company. Cantor Fitzgerald cut their target price on shares of Abeona Therapeutics from $28.00 to $21.00 and set an overweight rating for the company in a research note on Thursday, May 16th. Finally, StockNews.com cut shares of Abeona Therapeutics from a hold rating to a sell rating in a research note on Tuesday, April 23rd.

Abeona Therapeutics Trading Up 6.2 %

NASDAQ ABEO opened at $5.51 on Friday. The company has a market cap of $225.71 million, a P/E ratio of -1.72 and a beta of 1.59. Abeona Therapeutics has a 1 year low of $2.83 and a 1 year high of $9.01. The company has a fifty day simple moving average of $4.44 and a 200 day simple moving average of $5.62.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.06). Equities research analysts forecast that Abeona Therapeutics will post -1.81 EPS for the current fiscal year.

Insider Transactions at Abeona Therapeutics

In related news, Director Leila Alland acquired 11,000 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were purchased at an average price of $4.71 per share, with a total value of $51,810.00. Following the acquisition, the director now directly owns 82,857 shares in the company, valued at $390,256.47. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In other Abeona Therapeutics news, Director Leila Alland bought 11,000 shares of Abeona Therapeutics stock in a transaction dated Thursday, May 16th. The shares were bought at an average price of $4.71 per share, with a total value of $51,810.00. Following the purchase, the director now owns 82,857 shares of the company’s stock, valued at $390,256.47. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Brendan M. O’malley bought 8,600 shares of Abeona Therapeutics stock in a transaction dated Thursday, April 25th. The stock was acquired at an average cost of $3.24 per share, for a total transaction of $27,864.00. Following the purchase, the senior vice president now directly owns 188,718 shares in the company, valued at approximately $611,446.32. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 42,758 shares of company stock valued at $154,047. 5.30% of the stock is owned by insiders.

Institutional Trading of Abeona Therapeutics

Hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC acquired a new stake in Abeona Therapeutics during the 1st quarter worth approximately $91,000. Jump Financial LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at approximately $199,000. Western Standard LLC raised its holdings in shares of Abeona Therapeutics by 68.5% in the first quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock valued at $9,871,000 after purchasing an additional 553,377 shares during the last quarter. Finally, Rosalind Advisors Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $7,420,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.